Soligenix

322 articles with Soligenix

• Soligenix and the European Medicines Agency Pediatric Committee Reach Agreement on the Pediatric Investigation Plan for SGX942

  4/9/2019

  Acceptance of Pediatric Investigation Plan is important milestone on the path to submission of Marketing Authorization Application in Europe

• Soligenix Receives US Patent for Dusquetide Related Analogs

  4/4/2019

  Patent broadens protection in infectious disease and oral mucositis, including composition of matter claims

• Soligenix Announces Recent Accomplishments and Year-End 2018 Financial Results

  3/26/2019

  Soligenix, Inc. announced its recent accomplishments and financial results for the year ended December 31, 2018.

• Soligenix Announces Recent Accomplishments And Year-End 2018 Financial Results - March 26, 2019

  3/26/2019

  Soligenix, Inc announced its recent accomplishments and financial results for the year ended December 31, 2018.

• Soligenix to Present at National Institutes of Health - Commercialization Accelerator Program "FeedForward Session" in Washington, DC

  3/18/2019

  Soligenix, Inc. announced that they will be presenting at the National Institutes of Health - Commercialization Accelerator Program "FeedForward Session" in Washington, DC on March 21, 2019.

• Soligenix to Present at National Institutes of Health - Commercialization Accelerator Program "FeedForward Session" in Washington, DC

  3/18/2019

  Soligenix, Inc. announced today that they will be presenting at the National Institutes of Health (NIH) – Commercialization Accelerator Program (CAP) "FeedForward Session" in Washington, DC on March 21, 2019.

• Soligenix to Present at the Boston Oncology Investor Conference 2019

  3/11/2019

  Soligenix, Inc. announced that its Chief Scientific Officer, Oreola Donini, PhD, will deliver a corporate presentation at the Boston Oncology Investor Conference 2019 on Thursday, March 14 at 5:35 PM ET.

• Soligenix Corporate Presentation Webcast Recording

  2/25/2019

  An updated webcast of the Soligenix Corporate Presentation, given by Dr. Christopher J. Schaber, President and CEO, is available on the Company website. To listen and view the presentation, please visit www.soligenix.com.

• Zack's Investment Research, Inc. Research Report Update on Soligenix

  2/12/2019

  Analyst David Bautz, PhD of Zack's Investment Research, Inc. updated coverage on Soligenix, Inc. on February 12, 2019. For more information, please visit SCR.Zacks.com.

• Soligenix Receives US Patent Expanding Protection for its Ricin Toxin Vaccine, RiVax®

  2/11/2019

  Soligenix, Inc. announced the allowance of a new United States patent protecting its ricin toxin vaccine, RiVax®.

• Soligenix Receives US Patent Expanding Protection for its Ricin Toxin Vaccine, RiVax®

  2/11/2019

  Soligenix, Inc. announced the allowance of a new United States patent protecting its ricin toxin vaccine, RiVax®.

• Soligenix Announces Publication Demonstrating Thermostabilization of an Ebola Subunit Vaccine Candidate

  2/7/2019

  Soligenix, Inc. announced publication of a scientific article demonstrating the successful thermostabilization of an Ebola subunit vaccine candidate.

• 

  What's New in the Biodefense Market These Days?

  2/4/2019

  Although bioterrorism doesn’t get the kind of attention more traditional bombings and shootings receive, the biotech industry and the federal government are paying attention and actively funding and developing countermeasures to potential bioterror, military and public health emergencies.

• Soligenix Receives European Patent for Dusquetide and Related Innate Defense Regulator Analogs

  1/23/2019

  Patent broadens protection in infectious disease, including composition of matter claims

• Patent broadens protection in infectious disease, including composition of matter claims

  1/23/2019

  Patent broadens protection in infectious disease, including composition of matter claims   [23-January-2019]   PRINCETON, N.J. , Jan. 23, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical n

• Soligenix to Receive $611,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

  12/11/2018

  Soligenix, Inc. announced today that it has received preliminary approval for a tax credit from the New Jersey Economic Development Authority's (NJEDA) New Jersey Technology Business Tax Certificate Transfer program. 

• Maxim Group Research Report Update on Soligenix     

  12/6/2018

  Analyst Jason McCarthy, PhD of Maxim Group updated coverage on Soligenix, Inc. on December 6, 2018. For more information, please visit www.maximgrp.com.

• Soligenix Announces Publication of Scientific Review Discussing Clinical Applications of Innate Defense Regulator Technology

  12/5/2018

  Highlights Potential for Treating Multiple Diseases with Dusquetide and Related IDR Analogs

• Soligenix Selected to Present RiVax® Data at the Fourth International Conference on Vaccines Research & Development in Baltimore, Maryland

  11/12/2018

  Soligenix, Inc. announced that Dr. Oreola Donini, Chief Scientific Officer, will be presenting data from the ricin toxin vaccine (RiVax®) program describing development of the vaccine under the Food and Drug Administration (FDA) Animal Rule.

• Soligenix Announces Recent Accomplishments And Third Quarter 2018 Financial Results

  11/9/2018

  Soligenix, Inc. announced today its recent accomplishments and financial results for the third quarter ended September 30, 2018.